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Background: The incidence of anaemia is high in 
many chronic conditions, yet it often receives little 
attention.
Scope/methods: A panel of international experts 
with experience in haematology, nephrology, 
oncology, rheumatology and pharmacy was 
convened to prepare strategic guidelines. A 
focused literature search was conducted after 
key issues had been identified. A series of 
recommendations was agreed, backed, wherever 
possible, by published evidence which is included 
in the annotations.
Recommendations: Anaemia is a critical issue 
for patients with chronic diseases. Healthcare 
professionals need to recognise that anaemia 
is a frequent companion of cancer and chronic 
conditions such as rheumatoid arthritis and heart 
failure. It reduces patients’ quality of life and can 
increase morbidity and mortality. Anaemia should 
be considered as a disordered process in which 
the rate of red cell production fails to match the 
rate of destruction which leads eventually to a 
reduction in haemoglobin concentration; this 
process is common to all chronic anaemias. The 
aim of anaemia management should be to restore 
patient functionality and quality of life by restoring 
effective red cell production. Blood transfusion can 
elevate haemoglobin concentration in the short 
term but does nothing to address the underlying 
disorder; red cell transfusion is, therefore, not 
an appropriate treatment for chronic anaemia. 
Patients with anaemia of chronic disease may 
benefit from iron therapy and/or erythropoiesis 
stimulating agents (ESAs). Intravenous iron  
should be considered since this can be given 
safely to patients with chronic diseases while 
intramuscular iron causes unacceptable adverse 
effects and oral iron has limited efficacy in  
chronic anaemia.
Conclusion: The management of anaemia 
calls for the development of a specialist service 
together with education of all healthcare 
professionals and transfer of skills from areas of 
good practice. Improvement in the management 
of anaemia requires a fundamental change of 
attitude from healthcare professionals.
A B S T R A C T
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Introduction
Anaemia is common in patients with chronic condi­
tions of inflammation, infection or malignancy. Despite 
being the commonest side effect of cancer and cancer 
chemotherapy, and often having a profound effect on 
patients’ quality of life, anaemia remains an orphan 
issue. While lip service is paid by many clinicians to 
the importance of anaemia, it is often overlooked and 
undertreated. UK Anaemia called a meeting of experts 
from Europe and the United States of America with 
experience in haematology, nephrology, oncology, 
rheumatology and pharmacy to address these issues in 
May 2005. The aim was to develop recommendations 
on the approach to, and the management of, anaemia 
based on published evidence and practical experience.
The recommendations from the meeting take the 
form of a broad strategy. This should form the basis 
for more specific and detailed treatment guidelines 
which can be developed to meet the needs of different 
specialties and regions. Therapies are discussed 
generically, as the availability of treatments and 
diagnostic techniques vary between countries.
A focused literature search was performed after 
key issues had been identified. Publications were 
identified from Medline and from the reference lists 
of retrieved documents in addition to those identified 
by panel members. However, it became clear that the 
evidence base is incomplete and that many important 
questions about anaemia have not been raised, let alone 
answered. In developing the recommendations it was 
therefore necessary to extrapolate findings between 
different patient groups since the bulk of current 
knowledge stems from the experience of the use of 
erythropoietic and iron therapies in renal medicine. 
The recommendations are, therefore, evidence­based 
as far as possible but, when evidence is lacking, they are 
based on clinical experience. The underlying evidence 






Anaemia can significantly impair quality of life 
and is associated with increased morbidity and 
mortality1,2. In cancer patients, fatigue has a 
greater impact on daily life than pain3.
Anaemia and its associated symptoms affect not 
only patients with chronic diseases but also those 
caring for and living with them. A study from the 
United States has shown that cancer patients with 
anaemia require more care than those without 
anaemia and this has a direct impact on their 
families4.
Untreated anaemia can affect economic product­





•	 Anaemia is a critical issue for patients, especially those with chronic diseases. It can reduce patients’ quality 
of life and increase morbidity and mortality.
•	 Anaemia is a frequent companion of cancer and chronic conditions such as rheumatoid arthritis.
•	 Healthcare professionals too often accept anaemia and its consequences with equanimity – it is the patient 
who pays the price.
•	 There is a need to raise awareness of anaemia, its detection, investigation and management among 
healthcare professionals who treat patients with chronic diseases.
•	 Anaemia should be considered as a disordered process in which the rate of red cell production fails to match 
the rate of destruction, which eventually leads to a reduction in haemoglobin concentration – whatever the 
causation. This process is common to all chronic anaemias.
•	 The aim of anaemia management should be to restore patient functionality and quality of life, and to 
reduce morbidity and mortality, by restoring effective red cell production.
•	 Blood transfusion can elevate haemoglobin concentration in the short term but does nothing to address the 
underlying disorder. Red cell transfusion is not an appropriate treatment for chronic anaemia.
•	 Patients with anaemia of chronic disease may benefit from iron therapy and/or erythropoiesis stimulating 
agents (ESAs).
•	 Oral iron causes side­effects, is associated with drug–drug interactions, and has limited efficacy in chronic 
anaemia.
•	 Intramuscular iron is associated with unacceptable adverse effects and should not be given.
•	 Intravenous (iv) iron can be given safely to patients with chronic diseases.
•	 The management of anaemia calls for the development of a specialist service, education of all healthcare 
professionals and transfer of skills from areas of good practice.
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People with anaemia may not have access to 
information about their condition and may, there­
fore, be unaware of the treatment possibilities.
The long­term and widespread under­treatment 
of chemotherapy­induced anaemia may have 
contributed to the misconception that anaemia 
is an unavoidable consequence of cancer and its 
treatment7.
Until recently there have been no organisations 
representing people with anaemia. This contrasts 
with the rise of successful advocacy groups such 
as those for breast cancer which have lobbied 
effectively for better and more patient­centred care.
The World Health Organization estimates that 
‘as many as 4–5 billion people, 66–80% of the 
world’s population, may be iron deficient; 2 billion 





The recent European Cancer Anaemia Survey 
(ECAS), which involved over 15 000 patients in 
24 countries, found that about 40% of adult cancer 
patients had haemoglobin (Hb) concentration 
< 12 g/dL at the start of the survey. The incidence 
of anaemia rose to around 60% over the course of 
the survey9. A literature review has suggested that 
30–90% of patients with cancer are anaemic10.
Similarly, a Dutch study has found that about 
60% of patients with rheumatoid arthritis (RA) 
are anaemic11,12.
Long­term use of non­steroidal anti­inflammatory 
drugs (NSAIDs) can cause gastrointestinal blood 
loss resulting in iron­deficiency anaemia13.
Patients with chronic inflammatory conditions 
such as RA may also have inflammation­related 
anaemia14.
Renal impairment can cause anaemia; Hb concen­
trations are correlated with the glomerular filtration 
rate. The incidence of anaemia is relatively low 
in people with mild renal impairment but rises 
to over 90% in those receiving dialysis (if left 
untreated) and is independently associated with 
an increased risk of death.
Anaemia can be both a cause and a consequence 
of chronic heart failure (CHF) and can exacerbate 
symptoms of breathlessness and fatigue15. Falling 
haemoglobin concentrations in patients with CHF 
have been associated with increased morbidity 
and mortality16.
In patients with HIV, anaemia is a predictor 
of progression to AIDS and is independently 












A survey in the United States found that anaemia 
prevalence increased with age and that more than 
20% of those aged over 85 years were anaemic18.
Patients with chronic infection, inflammation or 
malignancy may also be prone to anaemia because 





Clinicians often underestimate the effects of anaemia 
on patients. However, studies have shown that cancer 






In the assessment of anaemia, many clinicians 
rely on one or two measurements taken from the 
blood count and chemistry. The selection of these 
measurements is often determined by history and 
availability.
Haemoglobin concentration is the key measure­
ment, but it is a late reflection of the anaemic 
process, and in some circumstances, chiefly 
pregnancy, may not reflect changes in the red cell 
mass. In some cultures, the haematocrit is used as 
a surrogate for measuring Hb concentration.
The productivity of the erythroid marrow can 
be assessed reliably using the reticulocyte count. 
The reticulocyte percentage can give an inverse 
reflection of red cell life span (when it is > 2.5% 
this is evidence of haemolysis).
The adequacy of iron supply to the developing 
erythron can be assessed from a variety of 
parameters, the most direct of which is the MCH 
(mean cell Hb). This is available as part of every 
full (complete) blood count but is rarely used. 
MCH is, however, a late reflection of the adequacy 
of iron supply. Mean cell volume (MCV) may 
mirror changes in MCH but can be confounded 
by a variety of factors. A more immediate measure 
of iron supply is provided by the reticulocyte Hb 
content while the percentage of hypochromic red 
cells offers an intermediate assessment (where 
these parameters are reported).
The adequacy of iron in reticuloendothelial iron 
‘stores’ can be assessed by measuring serum 
ferritin levels, but again there are a number of 
confounding factors. Ferritin is an acute phase 
reactant so this measure may be unreliable in 
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these ‘stores’ does not mean it is available for 
erythropoiesis. The flow of iron from these ‘stores’ 
to the marrow may be assessed by measurement 
of serum iron and Total Iron Binding Capacity 
(TIBC) but this measurement is biologically labile 
and methodologically often flawed.
In some circumstances, it may be appropriate to 
assess the stimulus to the marrow by measuring 
serum EPO or the degree of erythroid inhibition by 
an indicator of inflammation such as erythrocyte 









The red cell mass is maintained at a constant level 
by the balance of red cell production and destruc­
tion. Changes in this balance will be manifest 
as a change in Hb concentration. However, the 
relatively slow turnover of mature red cells means 
that this process has a high degree of inertia and a 
fall in Hb concentration is a very late reflection of 
the anaemia process19.
The making of red cells and the control of red cell 
production is fundamentally the same whatever 
the condition. In chronic conditions associated with 
infection, inflammation and malignancy, erythro­
poiesis will be suppressed by a common process 
involving the inflammatory cytokines. These counter 
the pro­erythropoietic activity of erythropoietin20.
A low Hb concentration is a consequence of a 
disordered erythropoietic process. Anaemia may 
be predicted from measures of erythropoietic 
activity by the reticulocyte count before Hb 
concentrations reach traditional levels at which 
anaemia is diagnosed21.
A low reticulocyte count (e.g. < 30 × 109/L), or 
falling Hb concentration should, therefore, be 
the stimulus to correct the disorder and prevent 
symptoms of anaemia.
Use of erythropoiesis stimulating agents (ESAs) 
without adequate iron support can create a 
Functional Iron Deficiency (FID) in which, although 
total iron storage levels may be normal, insufficient 
iron is transported to the bone marrow to support 
erythropoiesis22. FID is suggested by MCH < 28, 
reticulocyte Hb content < 29, hypochromic red 
cells > 5–10%; the transferrin saturation may be 
< 20%. Measurement of serum ferritin alone cannot 
indicate FID, since this can occur when the serum 












Several studies in patients with cancer, renal 
failure or inflammatory diseases have shown 
a correlation between correcting anaemia and 
improved quality of life23­26.
Anaemia is often diagnosed and treated by 
reference to the Hb concentration, but this is not 
directly related to what patients feel. Clinicians 
should, therefore, concentrate on preventing 
and alleviating the associated symptoms such as 
fatigue and breathlessness which can markedly 
impair functionality and lead to a vicious spiral of 






Transfusion of allogeneic blood or blood products 
is a logical approach to acute situations of blood 
loss such as trauma or surgery when patients 
require haemodynamic support. However, in cases 
of chronic inflammation, infection or malignancy, 
or when anaemia is caused iatrogenically by 
myelosuppression, the administration of blood or 
blood products has no effect on the disordered 
process and is, therefore, inappropriate.
The benefits of red blood cell transfusions have 
never been properly assessed, and their legendary 
life­saving properties have never been tested. 
Indeed, some studies have shown that transfusion 
is associated with a poorer prognosis in cancer 
patients1,27.
Clinical trials in which anaemic patients were 
randomised to receive an ESA or standard 
treatment (the control group) which consisted 
of blood transfusion have shown significant 
differences in quality of life between the ESA 
and control group. Patients in the control group 
received significantly more blood transfusions 
than those receiving an ESA yet tended to have a 
poorer quality of life24,26.
Clinical experience also suggests that transfusion­
dependent patients may have a poor quality of 
life despite maintaining Hb concentrations at 
acceptable levels. This contrasts with patients 
treated with ESAs supported with intravenous 
(iv) iron who often experience a noticeable 
improvement in quality of life almost immediately 











A number of ESAs have now been licensed for 
use in various countries, including darbepoetin 
alfa and two forms of recombinant human 
erythropoietin. The range of iv iron preparations 
available to clinicians has also increased recently 
with the introduction of iron sucrose and sodium 
ferric gluconate in addition to iron dextran.
In most countries, ESAs are used most extensively 
in renal dialysis patients, although their use in 
oncology is increasing, especially in patients 
receiving myelosuppressive chemotherapy28. The 
experience built up in renal units, including the 
optimisation of ESA therapy by the use of iv iron, 
should be transferred to other specialties. However, 
specific clinical trials should be performed in a 
number of chronic conditions for confirmation and 
to determine special considerations for different 
populations. Similarly, the different ESAs and iron 
preparations should be compared systematically to 
determine the best and most cost­effective treatment 
strategies29,30.
A study of 30 patients with rheumatoid arthritis and 
Hb < 12 g/dL (for women) or < 13 g/dL (for men) 
showed benefits of treatment with an ESA and iv 
iron in terms of the proportion of hypochromic 
red blood cells, serum ferritin concentration and 
quality of life (SF­36 measure of vitality)30.
The effectiveness of ESA treatment is enhanced by 
the co­administration of iv iron. Use of iv iron can 
accelerate or increase the response to the ESA31–34.
Use of iv iron may reduce the dose of ESA 
required to achieve a given response34.
In some cases, use of iv iron alone (i.e. without an 
ESA) can provide substantial improvements35–37.
Other adjuncts to ESAs (e.g. vitamin C, vitamin E, 
androgens, carnitine, pentoxifylline and statins) have 
not consistently been shown to be useful, or have 
been shown to pose an unacceptable risk of adverse 




In one study of 155 cancer patients (whose 
compliance with oral iron treatment was carefully 
monitored), the increase in Hb concentration 
in those receiving oral iron and an ESA was not 
significantly different from those who received no 
iron, whereas those receiving iv iron plus an ESA 
experienced a significant increase in Hb31.
In another study of dialysis patients receiving 










a significantly different response from those 
receiving no iron in terms of Hb and ferritin 
concentrations34.
Oral iron has several disadvantages including poor 
compliance and a high incidence of adverse gastro­
intestinal effects (nausea, vomiting, constipation, 
bloating and bleeding) and a high potential for 
interactions with other treatments.




Intramuscular iron is no more effective than iv iron 
but is painful to deliver and may cause staining 




Data from over 32 000 haemodialysis patients 
in the United States have shown no association 
between all­cause mortality and cumulative 
6­month iv iron dose42.
A French study of over 6000 patient­months 
of haemodialysis found no association between 
total dose of iv iron, or ferritin levels, and risk of 
infection43.
Serious adverse reactions to all iv iron preparations 
are rare44. Two studies have suggested that 
anaphylactic reactions with iron dextran occur 
with 0.6–0.7% of doses33,41. Another study reported 
lower rates of adverse events associated with low 
molecular weight iron dextran than with high 
molecular weight dextran44.
A recent analysis suggests rates of anaphylaxis 
of around three per million doses with iv iron 
dextran and less than one per million doses of iron 
gluconate or iron sucrose45.
The real clinical consequences of oxidative stress 
associated with free iron release after iv admin­
istration have not been determined.
Use of iv iron was traditionally avoided in RA 
because of concerns about disease flares. However, 
a more recent study has shown that not only may 
iv iron be given safely to people with RA, but its 
use, in combination with ESAs, is associated with 
a reduction in disease activity score30.
IV iron should not be given to patients with active 
sepsis46.
Animal studies using very high doses have 
suggested that iron may promote tumour growth 
but these findings have not been reflected in 
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to patients with normal levels of transferrin 
saturation. They may also not be relevant to the 
doses of iv iron given in normal clinical practice47. 
However, caution should be exercised in patients 
with high transferrin saturation (above 50%) since 
use of iv iron in this population may, theoretically, 
be associated with enhanced tumour growth or 
unwanted effects such as increased cardiotoxicity 
of chemotherapeutic agents48.
Bone marrow and tumour cells may compete 
for available iron. However, in patients with 
normal levels of transferrin saturation nearly all 
the iron from a therapeutic dose will be taken up 
by the bone marrow cells since their transferrin 
receptors are much more numerous, and have a 
greater affinity for iron, than those present on 
tumour cells. In addition, exposure of tumour 
cells to excess transferrin iron will be short­lived 






Following the recognition of the high prevalence 
of anaemia in patients undergoing dialysis, manage­
ment is currently coordinated best in renal 
medicine. According to international clinical prac­
tice guidelines, patients receiving dialysis now 
receive treatment with ESAs and iv iron2. However, 
in other specialties, training and experience in these 
therapies may be lacking and anaemia management 
is ill coordinated. The increasing specialisation 
within haematology has resulted in advances in 
the treatment of leukaemia but a decline in the 
treatment of anaemia49. The development of nurse 
consultants in anaemia (in the UK) serving a wide 
range of specialties, or other models involving other 
healthcare professionals with a focus on anaemia, 
may be the way forward.
Conclusions
Anaemia is important to patients. This is not generally 
appreciated in the clinical community. The need for 
specialist understanding and management of chronic 
anaemia is, as yet, poorly recognised and treatment is 
often poorly organized. We believe that it is now time 
to rectify these deficiencies. This may require funding 
but, more importantly, it will require a fundamental 
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